Abstract
Purpose :
To investigate the clinical outcomes and the safety profile of ab-interno canaloplasty (ABiC) with the iTrack microcatheter (Nova Eye Medical) in patients post-keratoplasty.
Methods :
A single-center, retrospective case series of eyes undergoing ABiC with or without phacoemulsification who had previously undergone keratoplasty was conducted. Factors including baseline and post-operative intraocular pressure (IOP), best corrected visual acuity (BCVA), and number ocular medications needed, along with post-operative complications at two years, was recorded. Statistical significance was defined as α = 0.05.
Results :
ABiC was successfully performed in 17 eyes after corneal surgery (8 PK, 6 DSEK, 2PK + DSEK, 1 DMEK). Baseline mean IOP (mmHg) was 26±6.8 and reduced to 13±2.9 and 14±3.3 at 1- and 2 years respectively (p<0.001). Baseline mean number of medications was 3.6±1.6 and was reduced to 2.9 ±1.3 and 3.2±1.8 at 1- and 2 years respectively (p=0.5). In the 12 eyes that received stand alone ABiC, IOP and medications reduced from 26.3±6.3 and 3.1±1.6 at baseline to 12.1±2.7 (p<0.001) and 2.8±1.4 (p=0.46) at 24-months. One patient had a hyphema which required washout. One patient required additional glaucoma surgery. No patients experienced worsening corneal edema or subsequent graft failure.
Conclusions :
This study suggests that ABiC can be safely and effectively performed in post-keratoplasty eyes without compromising graft survival. IOP reduction effects are maintained for at least two years.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.